Clinical trials: Malignant Melanoma
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating…
- Trial name
- NCT00089219
- Testing
- IFA, 6MHP, GM-CSF
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Virginia
Melanoma
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
- Trial name
- NCT00585000
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
End of Life, Advanced Cancer
Engagement of Patients With Advanced Cancer
The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced…
- Conditions
- End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer
- Trial name
- EPAC (NCT02966509)
- Testing
- EPAC
- Volunteers
- 213 people
- Sponsor
- Stanford University
Melanoma, Sentinel Lymph Node
The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study.
To evaluate the use of superparamagnetic iron oxide (Magtrace®) as a tracer in sentinel node biopsy in malignant melanoma of the extremities, and to evaluate the possible role of Magtrace®-MRI for staging.
- Trial name
- MAGMEN (NCT03898687)
- Testing
- SLN Biopsy with Magtrace®/Sentimag®
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Sahlgrenska University Hospital
Metastatic Melanoma
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
This is a single center, single arm phase I trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) followed by nivolumab rescue in unresectable locally advanced or metastatic…
- Trial name
- NCT03475134
- Testing
- TIL, Cyclophosphamide, Fludarabine
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Malignant Melanoma
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
- Trial name
- Pivotal (NCT02938299)
- Testing
- L19IL2 + L19TNF, Surgery
- Where
- 22 sites in France, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- Philogen S.p.A.
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Skin Cancer
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
The main purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of XL888 when administered orally with vemurafenib plus cobimetinib in participants with BRAF V600 mutated…
- Trial name
- NCT02721459
- Testing
- XL888, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
BRAF V600 Mutation, Unresectable Melanoma
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation.
- Conditions
- BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
- Trial name
- NCT04759846
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in Czechia, Italy and 1 more
- Sponsor
- Pierre Fabre Medicament
Melanoma
Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)
The purpose of this study is to calculate the sensitivity and specificity of a novel imaging device and associated software algorithm in detecting early stage melanoma versus nevi of the skin.
- Trial name
- NCT02470273
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Rockefeller University
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01814046
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
The Impact of Melanoma and Drug Treatment in the Real World
An observational, non-interventional registry study to collect real-world data from people living with melanoma and its treatment, which will be available to researchers to further the knowledge of melanoma and improve patient…
- Trial name
- NCT03379454
- Where
- United Kingdom
- Volunteers
- 819 people
- Sponsor
- Vitaccess Ltd
Autoimmunity, Melanoma
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
- Conditions
- Autoimmunity, Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Skin
- Trial name
- MINING (NCT03370861)
- Testing
- Immunotherapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Melanoma (Skin)
Melanoma Detection in Switzerland With VECTRA
This study is to compare 2D- and 3D-imaging and routine clinical care in early melanoma detection in a prospective large-scale real-world data set.
- Trial name
- MELVEC (NCT04605822)
- Testing
- 3D imaging Total Body Photography Vectra® WB360, 2D imaging FotoFinder ATBM® Master imaging system, Smartphone application (SkinVision®)
- Where
- Switzerland
- Volunteers
- 455 people
- Sponsor
- University Hospital, Basel, Switzerland
Uveal Melanoma
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.
- Trial name
- NCT03922880
- Testing
- ADI PEG20, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma Stage III
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival.
- Trial name
- Neo PeLe (NCT04207086)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Melanoma Institute Australia
Melanoma
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
To evaluate the safety and tolerability of intradermal injections of IMM-101 (Heat-killed Mycobacterium obuense) in melanoma cancer patients.
- Trial name
- NCT01308762
- Testing
- Heat killed whole cell M. obuense (IMM-101) 0.1 mg, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Immodulon Therapeutics Ltd
Malignant Melanoma, Lymph Node Disease
Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes
This trial seeks to establish the role of post-operative radiotherapy in patients who have had surgery for melanoma involving lymph nodes and who are at high risk of recurrence.
- Trial name
- NCT00287196
- Testing
- Radiotherapy
- Where
- 22 sites in Australia, Brazil and 2 more
- Volunteers
- 250 people
- Sponsor
- Trans Tasman Radiation Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.